We are live on ! Find out more
DM

Deerfield Management Portfolio holdings

AUM $8.48B
1-Year Est. Return 99.04%
This Fund
S&P 500
This Quarter Est. Return
-5.74%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$4.49B
AUM Growth
-$345M
Cap. Flow
-$1.43B
Cap. Flow %
-31.97%
Top 10 Hldgs %
44.77%
Holding
117
New
16
Increased
17
Reduced
12
Closed
11

Top Buys

Rank Stock Value
1
VTRS icon
Viatris
VTRS
+$76.9M
2
CPRX
Catalyst Pharmaceutical
CPRX
+$73.8M
3
AHCO icon
AdaptHealth
AHCO
+$54.6M
4
ACH
Accendra Health
ACH
+$48.2M
5
DCPH
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
+$47.9M

Top Sells

Rank Stock Value
1
PHR icon
Phreesia
PHR
+$44.2M
2
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$42M
3
IMGN
Immunogen Inc
IMGN
+$31.5M
4
AMLX icon
Amylyx Pharmaceuticals
AMLX
+$24.6M
5
RAIN
Rain Oncology Inc. Common Stock
RAIN
+$23.7M

Sector Composition

Rank Sector Weight
1 Healthcare 62.79%
2 Financials 0.36%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KURA icon
26
Kura Oncology
KURA
$981M
$29.1M 0.65%
2,383,000
– –
LUNG icon
27
Pulmonx
LUNG
$58.7M
$26.9M 0.6%
+2,402,704
New +$23.7M
DCGO icon
28
DocGo
DCGO
$64.2M
$26.5M 0.59%
+3,059,000
New +$27M
EWTX icon
29
Edgewise Therapeutics
EWTX
$4.33B
$26.2M 0.58%
3,933,137
– –
BLU
30
DELISTED
BELLUS Health Inc.
BLU
$25.8M 0.57%
3,581,000
– –
KRYS icon
31
Krystal Biotech
KRYS
$10.5B
$25M 0.56%
311,949
+136,949
+78% +$10.8M
TERN
32
DELISTED
Terns Pharmaceuticals
TERN
$24.4M 0.54%
2,059,421
-791,866
-28% -$7.57M
IDYA icon
33
IDEAYA Biosciences
IDYA
$3.49B
$23.9M 0.53%
1,743,628
– –
BCRX icon
34
BioCryst Pharmaceuticals
BCRX
$2.37B
$23.1M 0.51%
+2,765,000
New +$26.6M
WGS icon
35
GeneDx Holdings
WGS
$1.85B
$20.9M 0.47%
1,733,094
+1,428,571
+469% +$19M
VTYX
36
DELISTED
Ventyx Biosciences
VTYX
$20.7M 0.46%
+617,000
New +$24M
VIGL
37
DELISTED
Vigil Neuroscience
VIGL
$20.1M 0.45%
2,052,010
– –
VKTX icon
38
Viking Therapeutics
VKTX
$4.36B
$18.7M 0.42%
+1,125,000
New +$11.6M
GH icon
39
Guardant Health
GH
$20.3B
$18.3M 0.41%
+778,999
New +$22.3M
RVMD icon
40
Revolution Medicines
RVMD
$39.7B
$18M 0.4%
829,737
-61,850
-7% -$1.52M
ATEC icon
41
Alphatec Holdings
ATEC
$1.31B
$16.3M 0.36%
1,046,791
– –
DALS
42
DELISTED
DA32 Life Science Tech Acquisition Corp. Class A Common Stock
DALS
$16.2M 0.36%
1,600,000
– –
TARS icon
43
Tarsus Pharmaceuticals
TARS
$2.56B
$14.5M 0.32%
1,156,032
-168,182
-13% -$2.46M
DNLI icon
44
Denali Therapeutics
DNLI
$3.69B
$13.7M 0.31%
594,989
-205,011
-26% -$5.64M
ANAB icon
45
AnaptysBio
ANAB
$1.72B
$13.3M 0.3%
613,000
-548,826
-47% -$13.3M
ROIV icon
46
Roivant Sciences
ROIV
$25.1B
$12.9M 0.29%
+1,750,000
New +$14.4M
NVTA
47
DELISTED
Invitae Corporation
NVTA
$12.5M 0.28%
+9,274,707
New +$18.3M
MLYS icon
48
Mineralys Therapeutics
MLYS
$2.37B
$11.4M 0.25%
+729,021
New +$12.3M
INSM icon
49
Insmed
INSM
$23.6B
$11.2M 0.25%
658,546
-5,600
-0.8% -$109K
IOVA icon
50
Iovance Biotherapeutics
IOVA
$2.17B
$11.2M 0.25%
+1,831,607
New +$12.6M
1
2
3 4

Similar funds

FT
Fiduciary Trust Boston, Massachusetts $8.46B AUM 21.38% 1-Year Est. Return
GRQ
Gardner Russo & Quinn Lancaster, Pennsylvania $8.5B AUM 9.79% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
VA
Valmark Advisers Akron, Ohio $8.42B AUM 14.36% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $8.4B AUM 63.34% 1-Year Est. Return
IC
Icahn Carl Sunny Isles Beach, Florida $8.55B AUM 29.29% 1-Year Est. Return
NW
NewEdge Wealth Pittsburgh, Pennsylvania $8.39B AUM 24.47% 1-Year Est. Return
AAF
Andra AP-fonden Goteborg, Sweden $8.39B AUM 21.19% 1-Year Est. Return

Deerfield Management's Q1 2023 Portfolio in Review

As of Q1 2023, Deerfield Management held 117 positions worth $4.49B, down 7.1% from $4.83B the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Deerfield Management withdrew a net $1.43B in Q1 2023, closing 11 positions and reducing 12 holdings. Its most notable exit was Phreesia, an estimated $44.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 63% of assets, up from 56% a quarter earlier, followed by Financials.

Against the trend, Deerfield Management opened a new position in Intra-Cellular Therapies Inc. worth $39.7M.

  • Deerfield Management's largest Q1 2023 buy was Intra-Cellular Therapies Inc.: 734,000 shares worth $39.7M.
  • Deerfield Management added most to Viatris in Q1 2023, an estimated $76.9M increase.
  • Deerfield Management's biggest Q1 2023 reduction was IVERIC bio, Inc. Common Stock, cutting an estimated $42M.
  • Deerfield Management fully exited Phreesia in Q1 2023, selling an estimated $44.2M.
  • Deerfield Management's ten largest holdings make up 45% of its $4.49B portfolio in Q1 2023.
  • Deerfield Management opened 16 new positions and closed 11 in Q1 2023.
  • Deerfield Management's portfolio value fell 7.1% quarter-over-quarter to $4.49B.

Based on Deerfield Management's 13F filing for Q1 2023, filed 15 May 2023.